Trials Offered by a Specific Doctor

June Hou, MD

Dr. June Y. Hou received her undergraduate degree at Yale College with Honors, and completed medical school at Georgetown University School of Medicine. After completing her residency training at Yale New Haven Hospital, she pursued a gynecologic oncology fellowship at Albert Einstein College of Medicine, Montefiore Medical Center. She is board certified in Obstetrics and Gynecology, Gynecologic Oncology, and Palliative Medicine.

She joins the faculty at Columbia University Medical Center with a research interest in early phase clinical trials, and quality of life measures in patients undergoing clinical trials for gynecologic malignancies. A past recipient of a career development grant focusing on molecular pathogenesis of ovarian cancer and rare uterine cancers, Dr. Hou has given multiple nationally-recognized presentations based on her work, and has lead numerous clinical trials. Clinically, Dr. Hou is certified in minimally invasive surgery, including robotic-assisted surgery. Her expertise includes chemotherapeutics and complex pelvic surgeries. Her goal is to provide compassionate and individualized care to all women with pre-malignant or gynecological cancers.

Clinical Studies Managed By Dr. Hou:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for women with ovarian cancer who have failed chemotherapy using study drug Liposome-Encapsulated Doxorubicin HydrochlorideTolmarAAAQ6298
DetailsStudy of the Effects of Drug in Conjunction with Hormone Therapy in Patients with Endometrial CarcinomaXenetic BiosciencesAAAR4636
DetailsStudy of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsTESAROAAAR1665
DetailsStudy of REGN4018 Alone or in Combination with Cemiplimab in Patients with Ovarian CancerRegeneron Pharmaceuticals, Inc.AAAR8226
DetailsStudy of SPL-108 Injections Used in Combination with Paclitaxel in Patients with Advanced Ovarian Epithelial CancerSplash Pharmaceuticals, Inc.AAAR9030
DetailsStudy of SY-1365 in Adult Patients with Advanced Solid TumorsSyros Pharmaceuticals, Inc.AAAR9115
DetailsStudy of Tisotumab Vedotin (Investigational Drug) in Patients with Ovarian CancerSeattle Genetics, Inc.AAAS1622